Tech Company Financing Transactions
Deciphera Pharmaceuticals Funding Round
Deciphera Pharmaceuticals, based in Waltham, received $15 million in investment from SV Health Investors.
Transaction Overview
Company Name
Announced On
1/5/2016
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
SV Health Investors (Michael Ross)
Proceeds Purpose
SV Life Sciences' investment will contribute to rapid progression of Deciphera's lead tumor-targeting clinical programs, including Altiratinib and DCC-2618, as well as its immuno-targeted therapies such as DCC-3014 and Rebastanib, offering the potential to provide patients with innovative new therapeutic options while building a strong oncology-focused biotechnology company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Smith St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Deciphera Pharmaceuticals (NASDAQ: DCPH) was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 1/5/2016: Athletigen venture capital transaction
Next: 1/5/2016: RenovoRx venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs